• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Eli Lilly touts long-term safety data for Olumiant amid classwide scrutiny on JAK meds

cafead

Administrator
Staff member
  • cafead   Nov 10, 2021 at 10:02: PM
via Eli Lilly’s Olumiant has been dragged into a classwide safety review of JAK medicines that originated from Pfizer’s Xeljanz. Hoping to convince doctors that its offering doesn’t share the problems at the same magnitude, the Indianapolis pharma is turning to long-term data.

article source
 

<